# Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

> **NCT06999980** · PHASE2 · RECRUITING · sponsor: **Melanoma Institute Australia** · enrollment: 494 (estimated)

## Conditions studied

- Cutaneous Melanoma
- Mucosal Melanoma

## Interventions

- **DRUG:** Ipilimumab 3mg/kg and nivolumab 1mg/kg
- **DRUG:** Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg
- **DRUG:** Nivolumab 480mg and relatlimab 160mg
- **DRUG:** Ipilimumab 1mg/kg and nivolumab 3mg/kg
- **DRUG:** Pembrolizumab 200 mg

## Key facts

- **NCT ID:** NCT06999980
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2028-03
- **Final completion:** 2038-01
- **Target enrollment:** 494 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999980, "Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06999980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*